Eribulin drug could extend life of women with advanced triple negative breast cancer

[News]

THE cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday).

More... (http://www.news-medical.net/news/20141103/Eribulin-drug-could-extend-life-of-women-with-advanced-triple-negative-breast-cancer.aspx)